

OEBERGS contributes to malaria research

Press Release

October 21, 2015

Every minute an African child is killed by malaria.

Professor Mats Wahlgren at Karolinska Institutet, Stockholm, has together with Dilaforette AB developed a new treatment for severe malaria, Sevuparin™. This medicine prevents and reverses the ability of the parasitized red blood cells to block blood vessels. Sevuparin™ is ready for a phase II clinical trial, i.e. testing it on children in Africa. Professor Wahlgren, member of the Nobel Committee for Physiology or Medicine 2015, wants to start a “Malaria Foundation Sweden” to finance such a phase II study. OEBERGS has, on a pro bono basis, been given the assignment to structure the foundation.